A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)

Subjects

Subjects :

0301 basic medicine
Oncology
medicine.medical_specialty
business.industry
Afatinib
Low dose
Phases of clinical research
Hematology
medicine.disease
First line treatment
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Egfr mutation
030220 oncology & carcinogenesis
Internal medicine
Medicine
In patient
Non small cell
business
Lung cancer
medicine.drug

Details

ISSN :

09237534

Volume :

28

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........c962f4dbc1505c308af9a52033c75bb7

Full Text :

https://doi.org/10.1093/annonc/mdx671.054